Montay

Montai Health Adds Industry Leaders to its Board of Directors

Retrieved on: 
Wednesday, May 17, 2023
Technology, Research, Software, Biotechnology, Health, Pharmaceutical, Other Science, Science, Artificial Intelligence, Conditional sentence, Amgen, Human, Drug development, Senior, Marketing, Inflammation, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Research and development, Chemistry, Development, Neuroscience, Flagship Pioneering, Patient, AbbVie, Nature, Bunge Limited, Corporation, Autoimmune disease, Novo Nordisk, Biology, Artificial intelligence, Growth, AI, Therapy, International Flavors & Fragrances, Pharmaceutical industry, Management, Montay, Bayer

Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors.

Key Points: 
  • Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors.
  • "I'm thrilled to welcome Michael and Andreas to the board as we seize the unprecedented opportunity to address the global burden of chronic disease.
  • They are proven leaders with experience guiding companies through transformational growth and bring important and unique perspectives to Montai," said Margo Georgiadis, co-founder and CEO of Montai Health and CEO-Partner, Flagship Pioneering.
  • Mr. Fibig currently serves on the Board of Directors for Novo Nordisk and previously served on the Board of Directors for Bunge Limited.

Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide

Retrieved on: 
Tuesday, December 13, 2022
Former, Therapy, Conditional sentence, Ecosystem, Georgiadis, Indigo Agriculture, Parkinson's disease, SANA, Patient, Entrepreneurship, Science, Flagship, Biology, Flagship Pioneering, Disease, Drug development, Asthma, Investment, History, David Berry (inventor), MRNA, Human, Growth, Multimedia, Degenerative disease, Nature, Ancestor, Health, MBA, Management, Pharmaceutical industry, Montay

CAMBRIDGE, Mass., Dec. 13, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Montai Health, a company unlocking the power of nature with its CONECTA™ platform to create medicines that treat and preempt a broad range of chronic diseases. Flagship has initially committed $50 million to support the development of Montai's platform and its initial pipeline of new medicines. The company also announced that Margo Georgiadis, MBA, Flagship Pioneering CEO-Partner, who previously served as the CEO of Ancestry and President of the Americas at Google, is leading Montai as CEO. 

Key Points: 
  • Flagship has initially committed $50 million to support the development of Montai's platform and its initial pipeline of new medicines.
  • Montai is building the world's first Anthromolecule Bioactivity Atlas founded on a privileged class of molecules with a long history of safe, chronic human consumption.
  • "With Montai, we are asking the question what if the key to preempting or treating chronic disease exists within molecules we already consume," said Noubar Afeyan, Ph.D., Co-Founder of Montai Health and Founder and CEO, Flagship Pioneering.
  • "More than two billion people globally are affected by one or more chronic diseases, creating an unsustainable healthcare system and societal burden," said Margo Georgiadis, Co-Founder and CEO of Montai Health and CEO-Partner, Flagship Pioneering.